Single‐dose (4.5 mg/m <sup>2</sup> ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia-Reference-Cited by-同舟云学术

Single‐dose (4.5 mg/m ² ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia

Published:2022-04-19 Issue:2 Volume:198 Page:373-381
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Dhunputh Chloé¹,Strullu Marion²,Petit Arnaud³^ORCID,Merched Maria⁴,Pasquet Marlène⁵,Azarnoush Saba²,Leverger Guy³,Ducassou Stéphane¹^ORCID

Affiliation:

1. Paediatric Haematology Oncology Unit, CHU de Bordeaux Université de Bordeaux Bordeaux France

2. Paediatric Haematology Unit AP‐HP, Hopital Robert Débré, APHP Paris France

3. Sorbonne Université, Centre de Recherche Saint‐Antoine UMR_S938 Paediatric Haematology Oncology Unit, AP‐HP, Armand Trousseau Hospital Paris France

4. CIC Pédiatrique 1401 CHU Bordeaux France

5. Paediatric Haematology Oncology Unit CHU de Toulouse France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18203

Reference34 articles.

1. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012

2. Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01.

3. Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG